News

Eli Lilly Taps India as Global Pharma Export Base, Poised to Boost Logistics and Port Demand

US drugmaker Eli Lilly plans to leverage India’s manufacturing strength and a $1 billion investment to make the country a central export hub, a move expected to fuel cargo volumes through major Indian ports

• By PharmaNews Live Desk
• Hyderabad
• Feb 18, 2026

News

Eli Lilly and Company is positioning India as a vital global export base for its high-demand medicines, leveraging a previously announced $1 billion investment in contract manufacturing, industry and logistics sources said.

At the BioAsia conference in Hyderabad, Lilly India president Winselow Tucker outlined plans to integrate locally produced medicines into the multinational’s worldwide supply networks, especially following a sharp rise in demand for its blockbuster weight-loss drug Mounjaro.

“We are actually looking at India to be a hub, part of our global supply chain, and therefore supplying the world,” Tucker told reporters on the sidelines of the event, reiterating the company’s intent to capitalise on India’s contract manufacturing ecosystem to export medicines globally.

Lilly’s strategy comes amid doubling of Mounjaro sales in India soon after its launch, making it one of the company’s top-selling products by value in the market and affirming the country’s role in meeting rising obesity and metabolic disorder needs.

Logistics and Port Implications: Pharma Exports Set to Rise

Industry analysts said the shift toward India as an export base could add significant volumes to outbound shipping traffic and invigorate port operations at key gateways such as Chennai, Nhava Sheva (JNPT), and Mundra, especially for refrigerated (reefer) containers critical for pharma logistics.

Experts highlight that India’s robust cold-chain infrastructure and anticipated efficiencies in customs clearances under the Production Linked Incentive (PLI) scheme will further support a smoother flow of exports to major global markets including the United States, Europe and Southeast Asia.

Lilly’s new manufacturing oversight and quality hub in Hyderabad is expected to streamline operations and consolidate supply chains, presenting India as a competitive alternative to traditional export hubs in the Asia-Pacific region.

Product Pipeline and Competitive Landscape

Beyond Mounjaro, Lilly plans to bring additional medicines to and through India, including its Alzheimer’s drug donanemab and future treatments like the experimental oral weight-loss medication orforglipron, pending regulatory approvals.

The company also faces intensifying competition from Danish rival Novo Nordisk in obesity and metabolic therapies. However, Lilly executives reaffirmed confidence in its portfolio, noting pricing and clinical efficacy as key differentiators in a crowded market.

Market and Export Potential

India’s pharmaceutical industry is one of the world’s largest, supplying a substantial share of global generics and manufacturing medicines for over 200 countries, supported by a strong regulatory and production base.

Lilly’s move aligns with a broader industry trend where multinational pharmaceutical firms are increasingly using India not just as a commercial market but also as a manufacturing and export engine — a development that could reshape trade patterns and boost activity along the country’s maritime logistics corridors.